IFOM Pubblicazioni Alberto Bardelli
  1. Home
  2. Ricerca
  3. Pubblicazioni
  4. Pubblicazioni Alberto Bardelli

Pubblicazioni Alberto Bardelli

  1. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HC, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA
    Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
    Nat Med. 2016 Feb 1. [Epub ahead of print]

  2. Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Sartore Bianchi A, Li G, Siena S, Bardelli A
    Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.
    Cancer Discov. 2016 Jan;6(1):36-44

  3. Siravegna G, Bardelli A
    Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
    Mol Oncol. 2015 Dec 17. pii: S1574-7891(15)00241-06 [Epub ahead of print]

  4. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB.
    Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer.
    Cancer Discov. 2015 Dec 7. pii: CD-15-1283. [Epub ahead of print]

  5. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB.
    Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer.
    Cancer Discov. 2015 Dec;5(12):1271-81

  6. Prahallad A, Heynen GJJE, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R
    PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
    Cell Reports. 2015 Sep 29;12(12):1978-85

  7. Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC and Bardelli A
    Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
    Nat Commun. 2015 Sep 22;6:8305

  8. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CWM, Siu L, Snyder A, Stower H, Swanton C, Verhaak RGW, JC Zenklusen, Zuber J & Zucman-Rossi J
    Toward understanding and exploiting tumor heterogeneity
    Nat Med. 2015 Aug 6;21(8):846-53

  9. Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F
    Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
    Ann Oncol. 2015 Sep;26(9):1994-9

  10. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A
    Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
    Nat Med. 2015 Jul;21(7):795-801

  11. Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, Bardelli A, Seneci P, Walczak H, Delia D, Lecis D
    Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
    Oncotarget. 2015 May 10;6(13):10994-1008.

  12. Montagut C, Siravegna G, Bardelli A
    Liquid biopsies to evaluate early therapeutic response in colorectal cancer
    Ann Oncol. 2015 Aug;26(8):1525-7

  13. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sarote-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A
    The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
    Nat Commun. 2015 Apr 30;6:7002

  14. Arena S, Bellosillo B,Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A*, Montagut C* (*Co-Senior authors)
    Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
    Clin Cancer Res. 2015 May 1;21(9):2157-66

  15. Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R
    Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
    FASEB J. 2015 Feb;29(2):464-76

  16. Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez ME, Tabernero J, Villanueva J Circulating pEGFR is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer.
    Clin Cancer Res. 2014 Dec 15;20(24):6346-56

  17. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A.
    Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
    Cancer Discov. 2014 Nov;4(11):1269-1280

  18. Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A Mutational profiling of kinases in glioblastoma
    BMC Cancer. 2014 Sep 26;14:718

  19. Siravegna G, Bardelli A.
    Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance.
    Genome Biology. 2014 Aug 30;15(8):449.

  20. Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A
    RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
    Cell Rep. 2014 Sep 11;8(5):1475-83

  21. Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A
    TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells
    Clin Cancer Res. 2014 Dec 15;20(24):6429-38

  22. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A
    Acquired resistance to EGFR-targeted therapies in colorectal cancer
    Mol Oncol. 2014 Sep 12;8(6):1084-1094

  23. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A†, Trusolino L, Bernards R† (†Co-Senior authors)
    Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
    Cell Reports. 2014 Apr 10;7(1):86-93

  24. Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels L, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AMM, Bernards R
    Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    Nature. 2014 Apr 3;508(7494):118-22

  25. Siravegna G, Bardelli A.
    Minimal residual disease in breast cancer: in blood veritas.
    Clin Cancer Res. 2014 May 15;20(10):2505-7

  26. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr
    Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
    Sci Transl Med. 2014 Feb 19;6(224):224ra24

  27. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A
    Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer.
    Sci Transl Med. 2014 Feb 19;6(224):224ra26

  28. Diaz LA Jr, Bardelli A
    Liquid Biopsies: Genotyping Circulating Tumor DNA.
    J Clin Oncol. 2014 Feb 20;32(6):579-86

  29. Russo M, Di Nicolantonio F, Bardelli A
    Climbing RAS, the Everest of Oncogenes
    Cancer Discov. 2014 Jan;4(1):19-21

  30. Blair BG, Bardelli A, Park BH.
    Somatic alterations as the basis for resistance to targeted therapies.
    J Pathol. 2014 Jan;232(2):244-54

  31. Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A.
    Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels.
    Hum Mutat. 2014 Feb;35(2):208-14

  32. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F.
    BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
    Mol Cancer Ther. 2013 Dec;12(12):2950-61

  33. Bottos A, Bardelli A
    Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
    Cell Mol Life Sci. 2013 Nov;70(21):4131-40

  34. Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G.
    Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities.
    Cancer Treat Rev. 2013 Oct 23. pii: S0305-7372(13)00207-7

  35. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F
    KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
    Int J Cancer. 2013 Sep 1;133(5):1259-65

  36. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A
    Liquid biopsy: monitoring cancer-genetics in the blood
    Nat Rev Clin Oncol. 2013 Aug;10(8):472-84

  37. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz Jr LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F , Giordano S, Siena S
    Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
    Cancer Discov. 2013 Jun;3(6):658-7

  38. Di Nicolantonio F, Bardelli A
    Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?
    Clin Cancer Res. 2013 Jun 1;19(11):2794-6

  39. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P
    Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
    Clin Cancer Res. 2013 May 1;19(9):2381-92

  40. Martini M, Russo M, Lamba S, Vitiello E, Crowley EH, Sassi F, Romanelli D, Frattini M, Marchetti A, Bardelli A
    Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.
    Cancer Res. 2013 Mar 15;73(6):1912-21

  41. Zecchin D, Arena S, Martini M, Sassi F, Pisacane A, Di Nicolantonio F, Bardelli A
    Modeling Tumor Progression by the Sequential Introduction of Genetic Alterations into the Genome of Human Normal Cells.
    Hum Mutat. 2013 Feb;34(2):330-7

  42. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A
    Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer
    Nature. 2012 Jun 28;486(7404):532-6

  43. Cardone L, Bardelli A, Avvedimento VE
    Activation of β-Catenin by Oncogenic PIK3CA and EGFR Promotes Resistance to Glucose Deprivation by Inducing a Strong Antioxidant Response.
    PLoS One. 2012;7(5):e37526

  44. Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, Belvin M, Friedman LS.
    Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes.
    PLoS One. 2012;7(5):e36402

  45. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A
    Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Clin Cancer Res. 2012 May 1;18(9):2515-25

  46. Bardelli A, Janne PA
    The road to resistance: EGFR mutation and cetuximab
    Nat Med. 2012 Feb 6;18(2):199-200

  47. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R
    Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    Nature. 2012 Mar 01;483(7387):100-3

  48. Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A
    Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia
    Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9

  49. Martini M, Vecchione L, Siena S, Tejpar S and Bardelli A
    Targeted therapies: how personal should we go?
    Nat Rev Clin Oncol. 2012 Feb;9(2):87-97

  50. Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A
    KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment
    PLoS One. 2011;6(12):e29146

  51. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A† and Trusolino L&dagger (&daggerCo-Senior authors)
    A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
    Cancer Discov. 2011 Nov;1(6):508-23

  52. Rosa Roberta, Melisi Davide, Damiano Vincenzo, Bianco Roberto, Garofalo Sonia, Gelardi Teresa, Agrawal Sudhir, Di Nicolantonio Federica, Scarpa Aldo, Bardelli Alberto, Tortora Giampaolo (2011)
    Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Clinical cancer research 17(20),6531-41

  53. Molinari Francesca, Felicioni Lara, Buscarino Michela, De Dosso Sara, Buttitta Fiamma, Malatesta Sara, Movilia Alessandra, Luoni Marco, Boldorini Renzo, Alabiso Oscar, Girlando Salvatore, Soini Barbara, Spitale Alessandra, Di Nicolantonio Federica, Saletti Piercarlo, Crippa Stefano, Mazzucchelli Luca, Marchetti Antonio, Bardelli Alberto, Frattini Milo (2011)
    Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Clinical cancer research 17(14),4901-14

  54. Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S (2010)
    Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
    Cancer treatment reviews 36 Suppl 3(),S1-5

  55. Appendino Giovanni, Bardelli Alberto (2010)
    Broccoli, PTEN deletion and prostate cancer: where is the link?
    Molecular cancer 9(),308

  56. De Roock Wendy, Jonker Derek J, Di Nicolantonio Federica, Sartore-Bianchi Andrea, Tu Dongsheng, Siena Salvatore, Lamba Simona, Arena Sabrina, Frattini Milo, Piessevaux Hubert, Van Cutsem Eric, O\'Callaghan Chris J, Khambata-Ford Shirin, Zalcberg John R, Simes John, Karapetis Christos S, Bardelli Alberto, Tejpar Sabine (2010)
    Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    JAMA : the journal of the American Medical Association  304(16),1812-20

  57. Corbo Vincenzo, Ritelli Rossana, Barbi Stefano, Funel Niccola, Campani Daniela, Bardelli Alberto, Scarpa Aldo (2010)
    Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.
    PLoS one 5(9),e12653

  58. Bardelli Alberto, Siena Salvatore (2010)
    Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Journal of Clinical Oncology Mar 1;28(7); 1254-61

  59. Di Nicolantonio Federica, Arena Sabrina, Tabernero Josep, Grosso Stefano, Molinari Francesca, Macarulla Teresa, Russo Mariangela, Cancelliere Carlotta, Zecchin Davide, Mazzucchelli Luca, Sasazuki Takehiko, Shirasawa Senji, Geuna Massimo, Frattini Milo, Baselga JosÈ, Gallicchio Margherita, Biffo Stefano, Bardelli Alberto (2010)
    Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
    The Journal of clinical investigation 120(8),2858-66

  60. De Roock Wendy, Claes Bart, Bernasconi David, De Schutter Jef, Biesmans Bart, Fountzilas George, Kalogeras Konstantine T, Kotoula Vassiliki, Papamichael Demetris, Laurent-Puig Pierre, Penault-Llorca FrÈdÈrique, Rougier Philippe, Vincenzi Bruno, Santini Daniele, Tonini Giuseppe, Cappuzzo Federico, Frattini Milo, Molinari Francesca, Saletti Piercarlo, De Dosso Sara, Martini Miriam, Bardelli Alberto, Siena Salvatore, Sartore-Bianchi Andrea, Tabernero Josep, Macarulla Teresa, Di Fiore FrÈdÈric, Gangloff Alice Oden, Ciardiello Fortunato, Pfeiffer Per, Qvortrup Camilla, Hansen Tine Plato, Van Cutsem Eric, Piessevaux Hubert, Lambrechts Diether, Delorenzi Mauro, Tejpar Sabine (2010)
    Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    The lancet oncology 11(8),753-62

  61. Sartore-Bianchi Andrea, Bencardino Katia, Di Nicolantonio Federica, Pozzi Federico, Funaioli Chiara, Gambi Valentina, Arena Sabrina, Martini Miriam, Lamba Simona, Cassingena Andrea, Schiavo Roberta, Bardelli Alberto, Siena Salvatore (2010)
    Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Targeted oncology

  62. Loi Sherene, Haibe-Kains Benjamin, Majjaj Samira, Lallemand Francoise, Durbecq Virginie, Larsimont Denis, Gonzalez-Angulo Ana M, Pusztai Lajos, Symmans W Fraser, Bardelli Alberto, Ellis Paul, Tutt Andrew N J, Gillett Cheryl E, Hennessy Bryan T, Mills Gordon B, Phillips Wayne A, Piccart Martine J, Speed Terence P, McArthur Grant A, Sotiriou Christos (2010)
    PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Proceedings of the National Academy of Sciences 107(22),10208-13

  63. Barbi Stefano, Cataldo Ivana, De Manzoni Giovanni, Bersani Samantha, Lamba Simona, Mattuzzi Silvia, Bardelli Alberto, Scarpa Aldo (2010)
    The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
    Journal of experimental & clinical cancer research 29(),32

  64. Hudson Thomas J, Anderson Warwick, Artez Axel, Barker Anna D, Bell Cindy, BernabÈ Rosa R, Bhan M K, Calvo Fabien, Eerola Iiro, Gerhard Daniela S, Guttmacher Alan, Guyer Mark, Hemsley Fiona M, Jennings Jennifer L, Kerr David, Klatt Peter, Kolar Patrik, Kusada Jun, Lane David P, Laplace Frank, Youyong Lu, Nettekoven Gerd, Ozenberger Brad, Peterson Jane, Rao T S, Remacle Jacques, Schafer Alan J, Shibata Tatsuhiro, Stratton Michael R, Vockley Joseph G, Watanabe Koichi, Yang Huanming, Yuen Matthew M F, Knoppers Bartha M, Bobrow Martin, Cambon-Thomsen Anne, Dressler Lynn G, Dyke Stephanie O M, Joly Yann, Kato Kazuto, Kennedy Karen L, Nicol·s Pilar, Parker Michael J, Rial-Sebbag Emmanuelle, Romeo-Casabona Carlos M, Shaw Kenna M, Wallace Susan, Wiesner Georgia L, Zeps Nikolajs, Lichter Peter, Biankin Andrew V, Chabannon Christian, Chin Lynda, ClÈment Bruno, de Alava Enrique, Degos FranÁoise, Ferguson Martin L, Geary Peter, Hayes D Neil, Hudson Thomas J, Johns Amber L, Kasprzyk Arek, Nakagawa Hidewaki, Penny Robert, Piris Miguel A, Sarin Rajiv, Scarpa Aldo, Shibata Tatsuhiro, van de Vijver Marc, Futreal P Andrew, Aburatani Hiroyuki, BayÈs MÛnica, Botwell David D L, Campbell Peter J, Estivill Xavier, Gerhard Daniela S, Grimmond Sean M, Gut Ivo, Hirst Martin, LÛpez-OtÌn Carlos, Majumder Partha, Marra Marco, McPherson John D, Nakagawa Hidewaki, Ning Zemin, Puente Xose S, Ruan Yijun, Shibata Tatsuhiro, Stratton Michael R, Stunnenberg Hendrik G, Swerdlow Harold, Velculescu Victor E, Wilson Richard K, Xue Hong H, Yang Liu, Spellman Paul T, Bader Gary D, Boutros Paul C, Campbell Peter J, Flicek Paul, Getz Gad, GuigÛ Roderic, Guo Guangwu, Haussler David, Heath Simon, Hubbard Tim J, Jiang Tao, Jones Steven M, Li Qibin, LÛpez-Bigas Nuria, Luo Ruibang, Muthuswamy Lakshmi, Ouellette B F Francis, Pearson John V, Puente Xose S, Quesada Victor, Raphael Benjamin J, Sander Chris, Shibata Tatsuhiro, Speed Terence P, Stein Lincoln D, Stuart Joshua M, Teague Jon W, Totoki Yasushi, Tsunoda Tatsuhiko, Valencia Alfonso, Wheeler David A, Wu Honglong, Zhao Shancen, Zhou Guangyu, Stein Lincoln D, GuigÛ Roderic, Hubbard Tim J, Joly Yann, Jones Steven M, Kasprzyk Arek, Lathrop Mark, LÛpez-Bigas Nuria, Ouellette B F Francis, Spellman Paul T, Teague Jon W, Thomas Gilles, Valencia Alfonso, Yoshida Teruhiko, Kennedy Karen L, Axton Myles, Dyke Stephanie O M, Futreal P Andrew, Gerhard Daniela S, Gunter Chris, Guyer Mark, Hudson Thomas J, McPherson John D, Miller Linda J, Ozenberger Brad, Shaw Kenna M, Kasprzyk Arek, Stein Lincoln D, Zhang Junjun, Haider Syed A, Wang Jianxin, Yung Christina K, Cros Anthony, Cross Anthony, Liang Yong, Gnaneshan Saravanamuttu, Guberman Jonathan, Hsu Jack, Bobrow Martin, Chalmers Don R C, Hasel Karl W, Joly Yann, Kaan Terry S H, Kennedy Karen L, Knoppers Bartha M, Lowrance William W, Masui Tohru, Nicol·s Pilar, Rial-Sebbag Emmanuelle, Rodriguez Laura Lyman, Vergely Catherine, Yoshida Teruhiko, Grimmond Sean M, Biankin Andrew V, Bowtell David D L, Cloonan Nicole, deFazio Anna, Eshleman James R, Etemadmoghadam Dariush, Gardiner Brooke B, Gardiner Brooke A, Kench James G, Scarpa Aldo, Sutherland Robert L, Tempero Margaret A, Waddell Nicola J, Wilson Peter J, McPherson John D, Gallinger Steve, Tsao Ming-Sound, Shaw Patricia A, Petersen Gloria M, Mukhopadhyay Debabrata, Chin Lynda, DePinho Ronald A, Thayer Sarah, Muthuswamy Lakshmi, Shazand Kamran, Beck Timothy, Sam Michelle, Timms Lee, Ballin Vanessa, Lu Youyong, Ji Jiafu, Zhang Xiuqing, Chen Feng, Hu Xueda, Zhou Guangyu, Yang Qi, Tian Geng, Zhang Lianhai, Xing Xiaofang, Li Xianghong, Zhu Zhenggang, Yu Yingyan, Yu Jun, Yang Huanming, Lathrop Mark, Tost Jˆrg, Brennan Paul, Holcatova Ivana, Zaridze David, Brazma Alvis, Egevard Lars, Prokhortchouk Egor, Banks Rosamonde Elizabeth, UhlÈn Mathias, Cambon-Thomsen Anne, Viksna Juris, Ponten Fredrik, Skryabin Konstantin, Stratton Michael R, Futreal P Andrew, Birney Ewan, Borg Ake, B¯rresen-Dale Anne-Lise, Caldas Carlos, Foekens John A, Martin Sancha, Reis-Filho Jorge S, Richardson Andrea L, Sotiriou Christos, Stunnenberg Hendrik G, Thoms Giles, van de Vijver Marc, van\'t Veer Laura, Calvo Fabien, Birnbaum Daniel, Blanche HÈlËne, Boucher Pascal, Boyault Sandrine, Chabannon Christian, Gut Ivo, Masson-Jacquemier Jocelyne D, Lathrop Mark, PauportÈ Iris, Pivot Xavier, Vincent-Salomon Anne, Tabone Eric, Theillet Charles, Thomas Gilles, Tost Jˆrg, Treilleux Isabelle, Calvo Fabien, Bioulac-Sage Paulette, ClÈment Bruno, Decaens Thomas, Degos FranÁoise, Franco Dominique, Gut Ivo, Gut Marta, Heath Simon, Lathrop Mark, Samuel Didier, Thomas Gilles, Zucman-Rossi Jessica, Lichter Peter, Eils Roland, Brors Benedikt, Korbel Jan O, Korshunov Andrey, Landgraf Pablo, Lehrach Hans, Pfister Stefan, Radlwimmer Bernhard, Reifenberger Guido, Taylor Michael D, von Kalle Christof, Majumder Partha P, Sarin Rajiv, Rao T S, Bhan M K, Scarpa Aldo, Pederzoli Paolo, Lawlor Rita A, Delledonne Massimo, Bardelli Alberto, Biankin Andrew V, Grimmond Sean M, Gress Thomas, Klimstra David, Zamboni Giuseppe, Shibata Tatsuhiro, Nakamura Yusuke, Nakagawa Hidewaki, Kusada Jun, Tsunoda Tatsuhiko, Miyano Satoru, Aburatani Hiroyuki, Kato Kazuto, Fujimoto Akihiro, Yoshida Teruhiko, Campo Elias, LÛpez-OtÌn Carlos, Estivill Xavier, GuigÛ Roderic, de SanjosÈ Silvia, Piris Miguel A, Montserrat Emili, Gonz·lez-DÌaz Marcos, Puente Xose S, Jares Pedro, Valencia Alfonso, Himmelbauer Heinz, Himmelbaue Heinz, Quesada Victor, Bea Silvia, Stratton Michael R, Futreal P Andrew, Campbell Peter J, Vincent-Salomon Anne, Richardson Andrea L, Reis-Filho Jorge S, van de Vijver Marc, Thomas Gilles, Masson-Jacquemier Jocelyne D, Aparicio Samuel, Borg Ake, B¯rresen-Dale Anne-Lise, Caldas Carlos, Foekens John A, Stunnenberg Hendrik G, van\'t Veer Laura, Easton Douglas F, Spellman Paul T, Martin Sancha, Barker Anna D, Chin Lynda, Collins Francis S, Compton Carolyn C, Ferguson Martin L, Gerhard Daniela S, Getz Gad, Gunter Chris, Guttmacher Alan, Guyer Mark, Hayes D Neil, Lander Eric S, Ozenberger Brad, Penny Robert, Peterson Jane, Sander Chris, Shaw Kenna M, Speed Terence P, Spellman Paul T, Vockley Joseph G, Wheeler David A, Wilson Richard K, Hudson Thomas J, Chin Lynda, Knoppers Bartha M, Lander Eric S, Lichter Peter, Stein Lincoln D, Stratton Michael R, Anderson Warwick, Barker Anna D, Bell Cindy, Bobrow Martin, Burke Wylie, Collins Francis S, Compton Carolyn C, DePinho Ronald A, Easton Douglas F, Futreal P Andrew, Gerhard Daniela S, Green Anthony R, Guyer Mark, Hamilton Stanley R, Hubbard Tim J, Kallioniemi Olli P, Kennedy Karen L, Ley Timothy J, Liu Edison T, Lu Youyong, Majumder Partha, Marra Marco, Ozenberger Brad, Peterson Jane, Schafer Alan J, Spellman Paul T, Stunnenberg Hendrik G, Wainwright Brandon J, Wilson Richard K, Yang Huanming (2010)
    International network of cancer genome projects.
    Nature 464(7291),993-8

  65. Sartore-Bianchi Andrea, Bencardino Katia, Di Nicolantonio Federica, Pozzi Federico, Funaioli Chiara, Gambi Valentina, Arena Sabrina, Martini Miriam, Lamba Simona, Cassingena Andrea, Schiavo Roberta, Bardelli Alberto, Siena Salvatore (2010)
    Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Targeted oncology 5(1),19-28

  66. Zecchin Davide, Bardelli Alberto (2010)
    Tracking the genomic evolution of breast cancer metastasis.
    Breast cancer research : BCR 12(1),302

  67. Bleeker Fonnet E, Atai Nadia A, Lamba Simona, Jonker Ard, Rijkeboer Denise, Bosch Klazien S, Tigchelaar Wikky, Troost Dirk, Vandertop W Peter, Bardelli Alberto, Van Noorden Cornelis J F (2010)
    The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
    Acta neuropathologica 119(4),487-94

  68. Di Nicolantonio Federica, Arena Sabrina, Gallicchio Margherita, Bardelli Alberto (2010)
    Isogenic mutant human cells: a new tool for personalized cancer medicine.
    Cell cycle (Georgetown, Tex.) 9(1),20-1

  69. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A.
    Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. (2010)
    J Clin Invest. Aug 2;120(8):2858-66. doi: 10.1172/JCI37539.

  70. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.
    Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    (2010) Lancet Oncol. Aug;11(8):753-62.

  71. Siena S. and Bardelli A.
    Predictive markers for response to EGFR-targeted treatment in colorectal cancer (2010)
    Journal of Clinical Oncology in press

  72. Di Nicolantonio F, Arena S, Gallicchio and Bardelli A.
    Isogenic mutant human cells: A new tool for personalized cancer medicine.
    2010) Cell Cycle. Jan 1;9(1):20-1. Epub 2010 Jan 29.

  73. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.
    Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer.
    (2009) Journal of the National Cancer Institute. Oct 7;101(19):1308-24. Epub 2009 Sep 8. Review.

  74. Sartore-Bianchi A, Martini M, Molinari M, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena Sand Bardelli A.
    PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    (2009) Cancer Res. 1;69(5):1851-7.

  75. Bleeker FE, Lamba S, Rodolfo M, Scarpa A, Leenstra S, Vandertop WP and Bardelli A.
    Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes.
    (2009) Human Mutation. Feb;30(2):E451-9.

  76. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A and Bardelli A.
    IDH1 mutations at residue p.R132 (IDH1(R132) occur frequently in high-grade gliomas but not in other solid tumors.
    (2009) Human Mutation. Jan;30(1):7-11.

  77. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A.
    Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    (2008) Journal of Clinical Oncology. Dec 10;26(35):5705-12.

  78. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino M, Fantozzi R, Medico E and Bardelli A.
    Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.
    (2008) Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dec 30;105(52):20864-9.

  79. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Del Grammastro M, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A.
    AKT1 (E17K) in human solid tumours.
    Oncogene. May 26 [Epub ahead of print], 2008

  80. Arena S, Bardelli A.
    Understanding how kinase-targeted therapies work.
    Cell Cycle. Mar 30;7(11), 2008

  81. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A.
    PIK3CA cancer mutations display gender and tissue specificity patterns.
    Hum Mutat. Feb;29(2):284-8, 2008.

  82. Bleeker FE, Bardelli A.
    Genomic landscapes of cancers: prospects for targeted therapies.
    Pharmacogenomics. Dec;8(12):1629-33, 2007.

  83. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A.
    Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.
    Cancer Res. Sep 15;67(18):8468-76, 2007.

  84. Arena,S., Pisacane A., Mazzone, M., Comoglio P.M. and Bardelli A.
    Genetic targeting the kinase activity of the Met receptor in cancer cells.
    PNAS. vol 104, no.27, 11412-11417, 2007.

  85. Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C, Bardelli A.
    Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma.
    Cancer Res. Apr 15;67(8):3545-3550, 2007.

  86. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.
    Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
    Cancer Res. 2007 Mar 15;67(6):2643-8, 2007.

  87. Di Nicolantonio F. and Bardelli A.
    Kinase Mutations in Cancer: "Chinks in the Enemy's Armour?"
    Curr Opin Oncol. (1):69-76, 2006.

  88. Polato F., Codegoni A., Fruscio R., Perego P., Mangioni C., Broggini M., and Bardelli A*.
    PRL-3 phosphatase is implicated in ovarian cancer growth.
    (2005) Clinical Cancer Research. 11(19):6835-9, 2005. * Shared last authorship.

  89. Frattini M., Signoroni S., Pilotti S., Bertario L., Benvenuti S., Zanon C., Bardelli A., and Pierotti M.A.
    Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer.
    Cancer Res.; 65(23):11227, 2005.

  90. Parsons W.D.*, Samuels Y.*, Bardelli A.*, Silliman N., Saha S., Markowitz S., Willson J.K., Kinzler K.W., Vogelstein B., and Victor E. Velculescu.
    Mutational Analysis of the Serine/Threonine Kinome In Colorectal Cancers Identifies Alterations In PI3K Pathway Genes.
    Nature. Aug 11;436(7052):792, 2005. * Shared first authorship

  91. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., and Bardelli A.
    Copy number increase of the epidermal growth factor receptor gene is associated with clinical response of colorectal cancer to anti-EGFR antibody therapy.
    The LANCET Oncology 6(5):279-86, 2005.

  92. Bardelli A. and Velculescu V.
    Mutational profiling of gene families in cancer.
    Current Opinion in Genetics and Development, 15(1):5-12, 2005.

  93. Bentires-Alj M., Paez JG, David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., and Neel B.G.
    Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Cancer Res. Dec 15;64(24):8816-20, 2004.

  94. Wang Z. Shen D. Parsons D.W., Bardelli A., Sager J., Szabo S., Ptak J., Silliman N., Peters B.A., Van der Heijden M.S., Parmigiani G., Yan H., Wang T.L., Riggins G., Powell S.M., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E.
    Mutational analysis of the tyrosine phosphatome in colorectal cancers.
    Science. May 21;304(5674):1164-6, 2004.

  95. Samuels, Y., Wang, Z., Bardelli A., Ptak J., Szabo S., Silliman N., Scott K., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E.
    Mutations of the PIK3CA gene in human cancers.
    Science,: 304; 554-555, 2004.

  96. Bardelli A., Parsons W.D., Silliman N., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E.
    Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers.
    Science, 300:949, 2003.

  97. Bardelli A., Saha, S., Lengauer, C., Velculescu V.E., Kinzler, K.W. and Vogelstein B.
    PRL-3 Expession in metastatic cancers.
    Clinical Cancer Research, 9,5607-5615, 2003.

  98. Rajagopalan H, Bardelli A., Kinzler, K.W., Vogelstein B., and Velculescu V.E.
    RAF/RAS oncogenes and mismatch-repair status.
    Nature, 418:934, 2002.

  99. Bardelli A, Cahill D., Lederer G., Speicher M., Kinzler K., Vogelstein B. and Lengauer C.
    Carcinogen-Specific Induction of Genetic Instability.
    Proceedings of The National Academy Of Sciences 98(10) 5770-5775, 2001.

  100. Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St Croix B., Romans K.E., Choti M.A., Lengauer C., Kinzler K.W., and Vogelstein A.
    Phosphatase Associated With Metastasis of Colorectal Cancer.
    Science. 9;294:1343-6, 2001.
Alberto Bardelli Lab Bardelli Lab Ricercatore Programma di ricerca Stampa&Media Contatta il ricercatore